Advertisement
Research ArticleArticle

Transport of Temocaprilat into Rat Hepatocytes: Role of Organic Anion Transporting Polypeptide ,

Hitoshi Ishizuka, Kumiko Konno, Hideo Naganuma, Kenji Nishimura, Hirokazu Kouzuki, Hiroshi Suzuki, Bruno Stieger, Peter J. Meier and Yuichi Sugiyama
Journal of Pharmacology and Experimental Therapeutics October 1998, 287 (1) 37-42;

Abstract

The mechanism for hepatic uptake of temocaprilat, an angiotensin-converting enzyme inhibitor that is predominantly excreted into bile was studied using isolated rat hepatocytes and COS-7 cells expressing the organic anion transporting polypeptide (oatp1). The uptake of temocaprilat into isolated rat hepatocytes exhibited saturation with a Km of 20.9 μM and a Vmax of 0.21 nmol/min/mg protein. This uptake was temperature sensitive and was significantly reduced by metabolic inhibitors, a sulfhydryl-modifying reagent and an anion-exchange inhibitor, although the replacement of Na+ with Li+ in the medium did not affect the uptake. [3H]Temocaprilat uptake was inhibited by estradiol-17β-d-glucuronide and dibromosulphophthalein, typical substrates for the Na+-independent organic anion transporter, in a concentration-dependent manner, whereas excess estradiol-17β-d-glucuronide did not completely inhibit the uptake. Temocaprilat uptake into COS-7 cells transfected with oatp1 cDNA revealed a concentration-dependency with aKm of 46.7 μM, a value comparable with that obtained in isolated hepatocytes. The contribution of oatp1 to carrier-mediated hepatic uptake of temocaprilat was less than 50% by correcting the uptake clearance with that of estradiol-17β-d-glucuronide. A good linear correlation was observed for the inhibitory effect of angiotensin-converting enzyme inhibitors (benazeprilat, cilazaprilat, delaprilat and enalaprilat) between isolated hepatocytes and oatp1-expressing cells. These data suggest that oatp1, along with another transporter(s), mediates the uptake of angiotensin-converting enzyme inhibitors into rat hepatocytes.

Therapy with ACE inhibitors has become increasingly accepted over the past decade as a valuable option in the treatment of hypertension and congestive heart failure (Todd and Fitton, 1991). In general, ACE inhibitors are administered to patients as the prodrug (ethyl-ester). Recently, it was reported that treatment with an ACE inhibitor, temocapril · HCl (α-{(2S,6R)-6-[(1S)-1-ethoxy-carbonyl-3-phenyl-propyl]amino-5-oxo-2-(2-thienyl)perhydro-1,4-thiazepin-4-yl}acetic acid hydrochloride), improved forearm vasodilatory response to reactive hyperemia, suggesting a beneficial effect on endothelial function (Iwatsubo et al., 1997). To achieve optimal pharmaco-therapeutic efficacy, the pharmacokinetic behavior of ACE inhibitors has been studied extensively and it has been demonstrated that, as far as their excretion is concerned, many active forms of ACE inhibitors such as captopril (Brogden et al., 1988), enalaprilat (Todd and Goa, 1992), cilazaprilat (Deget and Brogden, 1991), ramiprilat (Frampton and Peters, 1995) and spiraprilat (Noble and Sorkin, 1995) are predominantly excreted into urine, whereas temocaprilat is excreted into bile after the oral administration of the respective prodrugs to humans; indeed, 36 to 44 and 17 to 24% of temocaprilat is excreted into feces and urine, respectively, 48 hr after oral administration of temocapril · HCl to humans (Suzukiet al., 1993). In rats, more than 80% of the dose is excreted into bile after i.v. administration (Ishizuka et al., 1997). The presence of an excretion route other than the urinary excretion provides a pharmacokinetic and pharmacodynamic advantage on temocapril over other ACE inhibitors, particularly in the treatment of patients with renal failure; in patients with severe renal insufficiency, the Cmax and AUC of enalaprilat increased 6 and 13 times, respectively, compared with normal volunteers, whereas the change in Cmax for temocaprilat was minimal and the AUC only doubled in the same patient populations (Oguchi et al., 1993).

One of the reasons for this efficient biliary excretion of temocapril is related to the transport properties of the cMOAT whose cDNA cloning and functional analysis have been performed by this and other laboratories (Paulusma et al., 1996; Büchler et al., 1996; Ito et al., 1997; Madon et al., 1997; Ito et al., 1998). Previously, we examined the hepatobiliary excretion of temocaprilat in SD rats and EHBR whose cMOAT is hereditarily defective (Ishizuka et al., 1997). We found that the clearance for the biliary excretion of temocaprilat after i.v. administration is lower in EHBR and that temocaprilat is taken up in an ATP-dependent manner by isolated bile canalicular membrane vesicles from SD rats but not from EHBR. Based on these findings, it was concluded that temocaprilat is a substrate of cMOAT. Kinetic analysis indicated that the Km of temocaprilat for cMOAT is 92.5 μM, which was in marked contrast to the low affinity of other ACE inhibitors (Ishizuka et al., 1997).

To compare the hepatobiliary excretion of temocaprilat with other ACE inhibitors, however, it is necessary to examine the uptake into hepatocytes from plasma across the basolateral membrane. It has been reported that many organic anions are transported into hepatocytes by active transport systems via Na+-dependent and -independent mechanisms (Meier, 1995; Müller and Jansen, 1997). Recently, two kinds of organic anion transporters have been cloned (Hagenbuchet al., 1991; Jacquemin et al., 1994). One of these is the Na+/taurocholate transporting polypeptide Ntcp by which several bile acids are transported (Hagenbuch et al., 1991; Stieger et al., 1994); another is the organic anion transporting polypeptide oatp1 that mediates the Na+-independent transport of many amphipathic substrates (Jacquemin et al., 1994; Bossuyt et al., 1996).

In our study, the hepatic transport system(s) responsible for the uptake of temocaprilat was characterized in relation to that of other ACE inhibitors. Because we found that temocaprilat is taken up by isolated hepatocytes in an Na+-independent manner, the role of oatp1 in the uptake of temocaprilat was investigated in transfected COS-7 cells.

Methods

Materials.

[3H]Temocaprilat (7.7 Ci/mmol) was synthesized by Daiichi Pure Chemicals Co. Ltd. (Tokyo, Japan). E217βG (47.3 Ci/mmol) was purchased from Du Pont New England Nuclear Corp. (Boston, MA). The radiochemical purity of the [3H]temocaprilat and [3H]E217βG determined by HPLC with radiodetector on a Zorbax ODS column was more than 97% for both compounds using the following mobile phases; 30 (acetonitrile): 70 (2% acetic acid, pH 3.0) and 55 (1% triethylammonium acetate, pH 4.0): 45 (methanol), respectively. Unlabeled temocaprilat was synthesized in our laboratories. Benazeprilat, cilazaprilat, delaprilat and enalaprilat were synthesized by the Institute of Science and Technology Inc. (Tokyo, Japan). COS-7 (ATCC 1651, African green monkey kidney cells) were purchased from the American Type Culture Collection (Rockville, MD). Full-length cDNA for oatp1 cloned in the plasmid pSPORT1 (Jacquemin et al., 1994) was excised with MluI to subclone it into the XhoI site in the pCAGGS vector (Niwaet al., 1991) after converting to blunt ends. Rotenone, FCCP, PCMBS, DIDS and E217βG were purchased from Sigma Chemical Co. (St. Louis, MO) and DBSP was from the Societéd’Etudes et de Recherches Biologiques (Paris, France). Male SD rats (8 wk old) were purchased from SLC Co., Ltd. (Shizuoka, Japan). All other chemicals used were commercially available and of reagent grade. Animal experiments were carried out according to the guidelines provided by the Institutional Animal Care Committee of Sankyo Co., Ltd. (Tokyo, Japan).

Uptake into isolated rat hepatocytes.

Hepatocytes were isolated from SD rats by the procedure described Baur et al.(1975), and were suspended in Krebs-Henseleit buffer supplemented with 12.5 mM HEPES (pH 7.4). Cell viability (>90%) was routinely checked by the trypan blue (0.4% w/v) exclusion test. The uptake study was performed as described in the previous report (Yamazaki et al., 1993). Briefly, the study was initiated by addition of ligand to the preincubated (37°C for 3 min) cell suspension (2 × 106 cells/ml). At designated times, the uptake was terminated by separating the cells from the medium using a centrifugal filtration technique (Schwenk, 1980), and the radioactivity in the cell and medium was determined in a liquid scintillation spectrophotometer (LSC-3500, Aloka Co., Tokyo, Japan). To minimize the contribution of surface binding, initial uptake velocity was calculated by linear regression of the uptake at 30, 60 and 90 sec, each time point of which was determined by the duplicate or triplicate experiments. For thecis-inhibition experiment, unlabeled ligands (E217βG or DBSP) were added to [3H]temocaprilat solution. Metabolic inhibitors, sulfhydryl-modifying reagent and anion exchange inhibitor, were added to the cell suspension 5 min before the addition of [3H]temocaprilat to examine their effect. To estimate the Na+-dependence of the uptake of temocaprilat, the experiments were performed in Krebs-Henseleit buffer with Na+ being replaced by Li+.

The effect of active metabolites of ACE inhibitors (benazeprilat, cilazaprilat, delaprilat and enalaprilat), dissolved in dimethylsulfoxide, on the uptake of [3H]temocaprilat was also studied. The final concentration of dimethylsulfoxide was less than 4%. A control experiment was also performed in the presence of the maximum concentration (4%) of organic solvent. Analyses of variance followed by Dunnett’s test was used to determine the significance of differences.

Uptake into COS-7 cells expressing oatp1.

COS-7 cells were cultured on 35-mm dishes in Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal bovine serum. At 80% confluence, cells were washed twice with DMEM without serum and then exposed to the solution containing plasmid (pcXN2 with or without oatp1, 10 μg/ml) and LipofectAMINE (10 μl/ml, Gibco BRL, Gaithersburg, MD). Eight hours after infection, plasmid-LipofectAMINE solution was removed and replaced by DMEM containing 10% bovine serum. The transfected cells were cultured overnight on a 12-well plate. Cells were washed with Krebs-Henseleit buffer to initiate the uptake experiments after preincubation (37°C) for 5 min. At designated times, uptake was terminated by removing the medium, and cells were washed with ice-cold PBS. Cells were then dissolved in 1N NaOH, and the radioactivity was determined in a liquid scintillation spectrophotometer (LSC-3500, Aloka Co., Tokyo, Japan). Initial uptake velocity was calculated by linear regression of the uptake at 30 and 90 sec, each time point of which was determined by the duplicate or triplicate experiments. The effect of unlabeled compounds on the uptake of radiolabeled substrates into the COS-7 cells was examined using the method described for the isolated hepatocytes.

Determination of kinetic parameters.

Uptake data were fitted to the following equation using the nonlinear least squares program, WinNonlin ver. 1.1 (Statistical Consultants Inc., Lexington, KY), to calculate the kinetic parameters:V=Vmax·CKm+C+Pdif·C Equation 1where V is the initial uptake rate, Vmax is the maximum uptake rate, Km is the Michaelis constant, C is the ligand concentration in the medium and Pdif is the non-specific uptake rate. Uptake clearance (CLuptake) was determined by the sum of Vmax/Km ratio and Pdif. For COS-7 cells, one nonlinear component model was used to fit the data subtracted nonspecific uptake portion by vector-transfected cells and the uptake clearance (CLuptake) was determined by the Vmax/Km ratio.

Contribution of oatp1 to carrier-mediated hepatic uptake of temocaprilat.

The contribution of oatp1 (Roatp1) to carrier-mediated uptake of temocaprilat into hepatocytes was estimated from equation 2:Roatp1=CLcos(temocaprilat)CLcos(E217βG)CLhep(temocaprilat)CLhep(E217βG) Equation 2where CLcos is the clearance for the uptake into oatp1-expressing COS-7 cells determined by the Vmax/Km ratio and CLhepis the uptake clearance into isolated hepatocytes determined by the Vmax/Km ratio.

Results

Uptake of temocaprilat into isolated hepatocytes.

Uptake of temocaprilat was linear over at least 2 min, and was significantly reduced at low temperature (fig. 1). Temocaprilat uptake into hepatocytes revealed concentration dependency (fig. 2) with a Km of 20.9 ± 8.0 μM, a Vmax of 0.21 ± 0.03 nmol/min/mg protein and a Pdif of 1.9 ± 0.3 μl/min/mg protein (mean ± S.E., N = 3) (table1). The uptake of E217βG also showed saturation (fig. 2) with a Km of 6.5 ± 1.6 μM and a Vmax of 0.47 ± 0.12 nmol/min/mg protein (mean ± S.E., N = 3) (table1). Temocaprilat uptake was inhibited by pretreatment with metabolic inhibitors such as rotenone (30 μM) or FCCP (2 μM), sulfhydryl-modifying reagent (PCMBS, 100 μM) and anion exchange inhibitor (DIDS, 100 μM), although the replacement of Na+by Li+ in the medium had no effect on temocaprilat uptake (table 2).

Figure 1
Figure 1

Time-profiles for the uptake of temocaprilat by isolated rat hepatocytes. The uptake of [3H]temocaprilat was measured by incubating isolated rat hepatocytes in Krebs-Henseleit buffer (pH 7.4) containing [3H]temocaprilat (0.1 μM) at 37°C (•) or 4°C (○) after preincubation for 3 min. Each point represents the mean ± S.E. of three different preparations.

Figure 2
Figure 2

Eadie-Hofstee plot for the uptake of temocaprilat (•) and E217βG (○) into isolated rat hepatocytes. Uptake of [3H]temocaprilat (0.1 μM) and [3H]E217βG (0.01 μM) into isolated hepatocytes was measured in the presence and absence of unlabeled temocaprilat and E217βG, respectively, in Krebs-Henseleit buffer (pH 7.4) at 37°C. Solid line represents the fitted line obtained from the kinetic parameters listed in table 1. Each point represents the mean ± S.E. of three to four different preparations.

View this table:
Table 1

Kinetic parameters for the transport of temocaprilat and E217βG (mean ± S.E., N = 3)

View this table:
Table 2

Characteristics of temocaprilat uptake into isolated hepatocytes (mean ± S.E., N = 3)

E217βG or DBSP, typical substrates for the Na+-independent organic anion transporter, inhibited temocaprilat uptake in a concentration-dependent manner (fig.3). Although a high concentration of DBSP completely inhibited the uptake of temocaprilat, its uptake was only partially inhibited by the addition of E217βG.

Figure 3
Figure 3

Effect of E217βG and DBSP on the uptake of temocaprilat into isolated rat hepatocytes. Uptake of [3H]Temocaprilat (0.1 μM) was measured in the presence of E217βG (left) and DBSP (right). Each point represents the percentage of the control value (mean ± S.E. of three different preparations).

Uptake of temocaprilat into COS-7 cells expressing oatp1.

Uptake of temocaprilat into COS-7 cells was significantly increased by transfecting oatp1 cDNA (fig.4). The concentration-dependent uptake of temocaprilat by oatp1-expressing COS-7 cells (fig.5) was described with aKm of 46.7 ± 15.9 μM and a Vmax of 0.092 ± 0.022 nmol/min/mg protein (mean ± S.E., N = 3) (table 1). The uptake of E217βG also showed saturation (fig. 5) with aKm of 11.0 ± 3.9 μM and a Vmax of 0.32 ± 0.16 nmol/min/mg protein (mean ± S.E., N = 3) (table 1). Uptake parameters for temocaprilat and E217βG obtained from both isolated hepatocytes (fig. 2) and oatp1-transfected COS-7 (fig. 5) experiments are summarized in table 1.

Figure 4
Figure 4

Time-profiles for the uptake of temocaprilat by oatp1 (•) and vector-transfected (○) COS-7 cells. Uptake of [3H]temocaprilat was measured by incubating COS-7 cells in Krebs-Henseleit buffer (pH 7.4) containing [3H]temocaprilat (0.1 μM) after preincubation for 5 min. Each point represents the mean ± S.E. of three different preparations.

Figure 5
Figure 5

Eadie-Hofstee plot for the uptake of temocaprilat (•) and E217βG (○) into oatp1-transfected COS-7 cells. Uptake of [3H]temocaprilat (0.1 μM) and [3H]E217βG (0.01 μM) into oatp1-transfected cells was measured in the presence and absence of unlabeled temocaprilat and E217βG, respectively. The initial uptake velocity for oatp1-mediated temocaprilat uptake was calculated by substracting the uptake for vector-transfected cells. Each point represents the mean ± S.E. of three to four different preparations.

The contribution of oatp1 (Roatp1) to carrier-mediated uptake of temocaprilat, calculated from equation 2, was 0.51, suggesting a significant contribution of oatp1 to the uptake of temocaprilat by rat hepatocytes.

Effect of other ACE inhibitors on the uptake of temocaprilat.

We examined the effect of benazeprilat, cilazaprilat, delaprilat and enalaprilat on the uptake of temocaprilat into liver. Uptake of [3H]temocaprilat was inhibited by these drugs (100 μM) in both isolated hepatocytes and oatp1-transfected COS-7 experiments (fig. 6). The degree of inhibition among ACE inhibitors exhibited a good linear correlation (r2 = 0.804) between both experiments.

Figure 6
Figure 6

Inhibitory effect of ACE inhibitors on the uptake of [3H]temocaprilat (0.1 μM) into isolated hepatocytes and oatp1-transfected COS-7 cells. Uptake of [3H]temocaprilat was measured in the presence of ACE inhibitors (100 μM) in both experiments. A good correlation (R2 = 0.804) was observed between both experiments. Each point represents the percentage of the control value (mean ± S.E. of three different preparations).

Discussion

The presence of the biliary excretion pathway confers a pharmacokinetic advantage on temocaprilat, particularly in the treatment of patients with renal failure. Although we found that temocaprilat is excreted into bile via cMOAT (Ishizuka et al., 1997), it is necessary to study the uptake of temocaprilat into hepatocytes across the basolateral membrane to account fully for the efficient biliary excretion of temocaprilat. Although temocaprilat is administered as the prodrug (temocapril · HCl), investigation of the hepatic uptake mechanism of temocaprilat is essential because it has been revealed that almost all the drug in portal blood at 3 or 5 min after intraduodenal administration of temocapril · HCl to rats is converted to temocaprilat (unpublished observation) and no other metabolites are found in plasma or bile (Ishizuka et al., 1997).

In our study, it was found that the uptake of temocaprilat by isolated rat hepatocytes is mediated by a Na+-independent mechanism (table 2). The Na+-independent transport system(s) on the sinusoidal membrane accounts for the hepatic uptake of many organic anions (Müller and Jansen, 1997); due to the broad substrate specificity, the putative transporter responsible for this uptake has been referred to as “multispecific organic anion transporter” (Meier, 1988). By examining the uptake into isolated hepatocytes, we and others have demonstrated that the substrates for this transporter include clinically important drugs such as DBSP (Blom et al., 1981), pravastatin (Yamazaki et al., 1993), benzylpenicillin (Tsuji et al., 1986), grepafloxacin (Sasabeet al., 1997) and conjugates of E3040 (Takenaka et al., 1997). Even a small peptide like BQ-123 is also partially transported into liver by this transport system (Nakamura et al., 1996).

Based on the expression cloning in Xenopus laevis oocytes, oatp1 has been cloned from rat liver as a transport carrier responsible for the Na+-independent uptake of organic anions (Jacqueminet al., 1994). This cloned oatp1 can, in fact, mediate the transport of a wide range of substrates as summarized by Meier et al. (1997). Because it was revealed that temocaprilat is taken up by isolated hepatocytes in a Na+-independent manner, we investigated if this transport is mediated by oatp1 by examining the uptake into COS-7 cells transiently expressing this cloned transporter. As the uptake of temocaprilat was significantly increased by transfecting oatp1 cDNA (fig. 4), we compared the uptake of temocaprilat with that of E217βG, a typical substrate for oatp1; based on studies using oatp1-injected oocytes, it has been shown that the Na+-independent uptake of E217βG into rat basolateral membrane vesicles is mediated by oatp1 (Bossuytet al., 1996; Meier et al., 1997). Kanai et al. (1996) determined the Km value for E217βG in oatp1-expressing HeLa cells as 3 μM. We also found a concentration-dependent uptake of E217βG in oatp1-expressing COS-7 cells with a Km of 11.0 μM (table 1), comparable with that reported by Kanai et al. (1996). In addition, the Km for the uptake of E217βG by hepatocytes (6.5 μM, table 1) was comparable with these Km values. These data indicate that COS-7 cells expressing oatp1 are suitable for estimating oatp1-mediated transport. At the present time, we do not have any good explanation to account for the low IC50 value of E217βG (0.8 μM) for the sensitive portion of temocaprilat uptake (fig. 3).

The contribution of oatp1 to carrier-mediated uptake of temocaprilat by isolated rat hepatocytes needs to be determined, however, because the uptake of temocaprilat was not completely inhibited by the addition of an excess of E217βG (fig. 3). We calculated this contribution as being approximately 50% by correcting the uptake clearance with that of E217βG (equation 2), suggesting the presence of another Na+-independent organic anion transport system(s) to account for the uptake of temocaprilat.

To estimate the contribution of oatp1 to the uptake of temocaprilat by isolated hepatocytes, we used E217βG as a reference compound because of its high affinity for oatp1 among the reported substrates (Meier et al., 1997). An underlying assumption with equation 2 is that E217βG is taken up into the hepatocytes predominantly by oatp1. This method has a limitation, however, because a recently cloned oatp1 homologue (oatp2) can also transport E217βG (Noé et al., 1997). If we consider that oatp2 is also responsible for the hepatic uptake of E217βG, the contribution of oatp1 calculated from equation 2 should overestimate the actual contribution,i.e., the contribution of oatp1 to the uptake of E217βG should be less than 50%. These results are also consistent with the hypothesis that another transporter(s) also mediates the uptake of temocaprilat. This hypothesis is further supported by the results of hepatocellular uptake study of temocaprilat. A high concentration of DBSP completely inhibited the uptake of temocaprilat, however, its uptake was only partially inhibited by the addition of E217βG (fig. 3). This inhibitory effect by DBSP on the uptake of temocaprilat may not result from the toxicity to cells; we previously examined the effect of DBSP on the uptake of grepafloxacin which was taken up by isolated rat hepatocytes via an active transport system distinct from organic anion transporter (Sasabe et al., 1997). The results showed that the transport of grepafloxacin was not affected by the addition of DBSP from 5 to 100 μM in the medium, although other drugs (such as quinidine and verapamil) inhibited the uptake of grepafloxacin. Therefore, the effect of DBSP on the uptake of temocaprilat shown in fig. 3 may not result from the toxicity to cells, but predominantly from its inhibitory effect on the transporter(s). Moreover, the effect of metabolic inhibitors on the uptake of temocaprilat was observed by the isolated hepatocytes (table 2). We found that the transport of temocaprilat was at least in part mediated by oatp1, which can act as a bicarbonate exchanger (Satlin et al., 1997). The addition of metabolic inhibitor reduced the driving force for the uptake, resulting in a reduction of temocaprilat uptake.

To determined the kinetic parameters for the uptake of temocaprilat, we fitted the data obtained from isolated hepatocytes to equation 1. In our preliminary results, the uptake of temocaprilat into isolated hepatocytes at 4°C increased linearly against the medium concentration and the data (Pdif) obtained was comparable with the fitted values calculated from equation 1 (1.6 vs.1.9, data not shown). We tried to calculate the uptake parameters using a model consisting of two transport components, in addition to the nonspecific component. However, meaningless values were obtained for some parameters because of the deviation in the data and because the number of parameters (five parameters containingKm1 , Km2 , Vmax1, Vmax2 and Pdif) were excessive compared with the number of data points (six parameters).

The presence of multiple transport systems for the uptake of organic anions by the hepatocytes has been suggested previously and an oatp2 has been isolated recently (Noé et al., 1997). To evaluate the extent to which oatp1 accounts for the hepatic uptake of BSP, Hagenbuch et al. (1996) used an antisense oligonucleotide. Oatp1-specific antisense oligonucleotides were coinjected with total rat liver mRNA into Xenopus laevisoocytes to measure the uptake of BSP. The results indicated that oatp1 accounts for only half of total BSP transport, also suggesting the presence of additional organic anion uptake systems in rat liver (Hagenbuch et al., 1996). In addition, Horz et al. (1996) examined the uptake of bumetanide into oocytes injected with cRNA for ntcp or oatp1 and suggested the presence of an organic anion transport system that is different from these transporters. Thus, temocaprilat may be additionally transported by other organic anion transporter(s) including oatp2 (Meier et al., 1997).

Other ACE inhibitors have also some affinity for oatp1, since they inhibited the uptake of temocaprilat into oatp1-expressing COS-7 cells (fig. 6). In addition, these ACE inhibitors may also have some affinity for the unidentified transporter(s), because the inhibitory effect of ACE inhibitors on the uptake of temocaprilat correlated well between isolated hepatocytes and oatp1-transfected cells (fig. 6). Recently, using a Hela cell line stably expressing oatp1, it was also reported that oatp1 mediates the uptake of enalapril although the uptake of enalaprilat was not studied (Pang et al., 1997). Collectively, it is possible that oatp1 contributes to the sinusoidal uptake of these ACE inhibitors, although their predominant excretion pathway, except in the case of temocaprilat, is via urine. In our previous report, we demonstrated that temocaprilat is efficiently excreted into bile via cMOAT for which other ACE inhibitors, such as benazeprilat, cilazaprilat, delaprilat, enalaprilat and imidaprilat, have a low affinity (Ishizuka et al., 1997). Taking these data into account, it is suggested that, although ACE inhibitors other than temocaprilat may be transported efficiently into hepatocytes, most of the drug may be released into the systemic circulation and, finally, excreted via urine. The affinity for cMOAT is the predominant reason accounting for the difference in the excretion pathway between temocaprilat and other ACE inhibitors.

In conclusion, our results indicate that temocaprilat is taken up by rat isolated hepatocytes via an Na+-independent mechanism, approximately half of which is mediated by oatp1. Although other ACE inhibitors may be taken up by hepatocytes, the fact that they are almost exclusively excreted via urine may be accounted for by their low affinity for cMOAT.

Footnotes

  • Send reprint requests to: Dr. Hitoshi Ishizuka, Analytical and Metabolic Research Laboratories, Sankyo Co., Ltd., 2-58, Hiromachi 1-chome, Shinagawa-ku, Tokyo 140, Japan.

  • ↵1 This work was supported in part by the Swiss National Science Foundation Grant 31-45536.95 to P.J.M.

  • ↵2 This work was supported in part by a grant-in-aid from the Ministry of Education, Science, Sports and Culture of Japan, and the Core Research for Evolutional Sciences and Technology of Japan Sciences and Technology Corporation.

  • Abbreviations:
    ACE
    angiotensin-converting enzyme
    oatp1
    organic anion transporting polypeptide
    Ntcp
    Na+/taurocholate co-transporting polypeptide
    cMOAT
    canalicular multispecific organic anion transporter
    E217βG
    estradiol-17β-d-glucuronide
    BSP
    bromosulfophthalein
    DBSP
    dibromosulfophthalein
    DIDS
    4,4′-diisothiocyanostilbene-2,2′-disulfonic acid
    FCCP
    carbonyl cyanide p-(trifluoro-methoxy)phenylhydrazone
    PCMBS
    p-choloromercuriphenylsulfonic acid
    HEPES
    2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid
    SD rats
    Sprague-Dawley rats
    EHBR
    Eisai hyperbilirubinemic rats
    DMEM
    Dulbecco’s modified Eagle’s medium
    • Received January 17, 1998.
    • Accepted May 18, 1998.

References

  1. ↵
    1. Baur H,
    2. Kasperek S,
    3. Pfaff E
    (1975) Criteria of viability of isolated liver cells. Hoppe-Seyler Z Physiol Chem 356:827–838.
    OpenUrlPubMed
  2. ↵
    1. Blom A,
    2. Keulemans K,
    3. Meijer DKF
    (1981) Transport of dibromosulfophthalein by isolated rat hepatocyte. Biochem Pharm 30:1809–1816.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Bossuyt X,
    2. Müller M,
    3. Hagenbuch B,
    4. Meier PJ
    (1996) Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther 276:891–896.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Brogden RN,
    2. Todd PA,
    3. Sorkin EM
    (1998) Captopril: An update its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drug 36:540–600.
    OpenUrlCrossRef
  5. ↵
    1. Büchler M,
    2. König J,
    3. Brom M,
    4. Kartenbeck J,
    5. Spring H,
    6. Horie T,
    7. Keppler D
    (1996) cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J Biol Chem 271:15091–15098.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Deget F,
    2. Brogden RN
    (1991) Cilazapril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiovascular disease. Drugs 41:799–820.
    OpenUrlPubMed
  7. ↵
    1. Frampton JE,
    2. Peters DH
    (1995) Ramipril: An updated review of its therapeutic use in essential hypertension and heart failure. Drugs 49:440–466.
    OpenUrlPubMed
  8. ↵
    1. Hagenbuch B,
    2. Stieger B,
    3. Froguet M,
    4. Lübbert H,
    5. Meier PJ
    (1991) Functional expression cloning and characterization of the hepatocyte Na+/bile acid cotransport system. Proc Natl Acad Sci USA 88:10629–10633.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Hagenbuch B,
    2. Scharschmidt BF,
    3. Meier PJ
    (1996) Effect of antisense oligonucleotides on the expression of hepatocellular bile acid and organic anion uptake systems in Xenopus laevis oocytes. Biochem J 316:901–904.
  10. ↵
    1. Horz JA,
    2. Honscha W,
    3. Petzinger E
    (1996) Bumetanide is not transported by the Ntcp or by the oatp1: Evidence for a third organic anion transporter in rat liver cells. Biochim Biophys Acta 1300:114–118.
    OpenUrlPubMed
  11. ↵
    1. Ishizuka H,
    2. Konno K,
    3. Naganuma H,
    4. Sasahara K,
    5. Kawahara Y,
    6. Niinuma K,
    7. Suzuki H,
    8. Sugiyama Y
    (1997) Temocaprilat, a novel angiotensin converting enzyme inhibitor, is excreted into bile via an ATP-dependent active transporter (cMOAT) that is deficient in Eisai hyperbilirubinemic mutant rats (EHBR). J Pharmacol Exp Ther 280:1304–1311.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Ito K,
    2. Suzuki H,
    3. Hirohashi T,
    4. Kume K,
    5. Shimizu T,
    6. Sugiyama Y
    (1997) Molecular cloning of canalicular multispecific anion transporter defective in Eisai hyperbilirubinemic rats. Am J Physiol 272:G16–G22.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Ito K,
    2. Suzuki H,
    3. Hirohashi T,
    4. Kume K,
    5. Shimizu T,
    6. Sugiyama Y
    (1998) Functional analysis of a canalicular multispecific organic anion transporter cloned from rat liver. J Biol Chem 273:1684–1688.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Iwatsubo H,
    2. Nagano M,
    3. Sakai T,
    4. Kumamoto K,
    5. Morita R,
    6. Higaki J,
    7. Ogihara T,
    8. Hata T
    (1997) Converting enzyme inhibitor improves forearm reactive hyperemia in essential hypertension. Hypertension 29(1 Pt 2):286–290.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Jacquemin E,
    2. Hagenbuch B,
    3. Stieger B,
    4. Wolkoff AW,
    5. Meier PJ
    (1994) Expression cloning of a sodium-independent organic anion uptake system of rat liver. Proc Natl Acad Sci USA 91:133–137.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Kanai N,
    2. Run L,
    3. Yi B,
    4. Wolkoff AW,
    5. Vore M,
    6. Schuster VL
    (1996) Estradiol 17β-d-glucuronide is a high-affinity substrate for oatp1 organic anion transporter. Am J Physiol 270:F326–F331.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Madon J,
    2. Eckhardt U,
    3. Gerloff T,
    4. Stieger B,
    5. Meier PJ
    (1997) Functional expression of the rat liver canalicular isoform of the multi drug resistance-associated protein. FEBS Lett 406:75–78.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Meier PJ
    (1988) Transport polarity of hepatocytes. Semin Liver Dis 8:293–307.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Meier PJ
    (1995) Molecular mechanisms of hepatic bile salt transport from sinusoidal blood into bile. Am J Physiol 32:G801–G812.
    OpenUrl
  20. ↵
    1. Meier PJ,
    2. Eckhardt U,
    3. Schroeder A,
    4. Hagenbuch B,
    5. Stieger B
    (1997) Substrate specificity of the sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology 26:1667–1677.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Müller M,
    2. Jansen PLM
    (1997) Molecular aspects of hepatobiliary transport. Am J Physiol 272:G1285–G1303.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Nakamura T,
    2. Hisaka A,
    3. Sawasaki Y,
    4. Suzuki Y,
    5. Fukami T,
    6. Ishikawa K,
    7. Yano M,
    8. Sugiyama Y
    (1996) Carrier-mediated active transport of BQ-123, a peptidic endothelin antagonist, into rat hepatocytes. J Pharmacol Exp Ther 278:564–572.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Niwa H,
    2. Yamamura K,
    3. Miyazaki J
    (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108:193–199.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Noble S,
    2. Sorkin EM
    (1995) Spirapril: A preliminary review of its pharmacology and therapeutic efficacy in treatment of hypertension. Drugs 49:750–766.
    OpenUrlPubMed
  25. ↵
    1. Noé B,
    2. Hagenbuch B,
    3. Stieger B,
    4. Meier PJ
    (1997) Isolation of a multispecific organic anion and cardiac glycoside transporters from rat brain. Proc Natl Acad Sci USA 94:10346–10350.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Oguchi H,
    2. Miyasaka M,
    3. Koiwai T,
    4. Tokunaga S,
    5. Hara K,
    6. Sato K,
    7. Yoshie T,
    8. Shioya H,
    9. Furuta S
    (1993) Pharmacokinetics of temocapril and enalapril in patients with various degrees of renal insufficiency. Clin Pharmacokinet 24:421–427.
    OpenUrlPubMed
  27. ↵
    1. Pang KS,
    2. Wang PJ,
    3. Chung A,
    4. Wolkoff AW
    (1997) The dipeptide enalapril, an angiotensin converting enzyme inhibitor, is transported by the rat liver organic anion transport protein (OATP1). Hepatology 26:129A.
    OpenUrlPubMed
  28. ↵
    1. Paulusma CC,
    2. Bosma PJ,
    3. Zaman GJR,
    4. Bakker CTM,
    5. Otter M,
    6. Scheffer GL,
    7. Scheper RSJ,
    8. Borst P,
    9. Oude Elferink PJ
    (1996) Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 271:1126–1128.
    OpenUrlAbstract
  29. ↵
    1. Sasabe H,
    2. Terasaki T,
    3. Tsuji A,
    4. Sugiyama Y
    (1997) Carrier-mediated hepatic uptake of quinolone antibiotics in the rat. J Pharmacol Exp Ther 282:162–171.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Satlin LM,
    2. Amin V,
    3. Wolkoff AW
    (1997) Organic anion transporting polypeptide mediates organic anion/HCO3-exchange. J Biol Chem 272:26340–26345.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Schwenk M
    (1980) Transport systems of isolated hepatocytes. Studies on the transport of biliary compounds. Arch Toxicol 44:113–126.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Stieger B,
    2. Hagenbuch B,
    3. Landmann L,
    4. Höchli M,
    5. Schroeder A,
    6. Meier PJ
    (1994) In situ localization of the hepatocytic Na+/Taurocholate cotransporting polypeptide in rat liver. Gastroenterology 107:1781–1787.
    OpenUrlPubMed
  33. ↵
    1. Suzuki H,
    2. Kawaratani T,
    3. Shioya H,
    4. Uji Y,
    5. Saruta T
    (1993) Study on pharmacokinetics of a new biliary excreted oral angiotensin converting enzyme inhibitor, temocapril (CS-622) in humans. Biopharm Drug Dispos 14:41–50.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Takenaka O,
    2. Horie T,
    3. Suzuki H,
    4. Sugiyama Y
    (1997) Carrier-mediated active transport of glucuronide and sulfate of 6-hydroxy-5, 7-dimethyl-2-methylamino-4-(3-pyridylmethl)benzothiazole (E3040) into rat liver: quantitative comparison of permeability in isolated hepatocytes, perfused liver and liver in vivo. J Pharmacol Exp Ther 280:948–958.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Todd PA,
    2. Fitton A
    (1991) Perindopril: A review of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 42:90–114.
    OpenUrlPubMed
  36. ↵
    1. Todd PA,
    2. Goa KL
    (1992) Enalapril: A reappraisal of its pharmacology and therapeutic use in hypertension. Drugs 43:346–381.
    OpenUrlPubMed
  37. ↵
    1. Tsuji A,
    2. Terasaki T,
    3. Takanosu T,
    4. Tamai I,
    5. Nakashima E
    (1986) Uptake of benzylpenicillin, cefpiramide and cefazolin by freshly prepared rat hepatocytes. Biochem Pharmacol 35:151–158.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Yamazaki M,
    2. Suzuki H,
    3. Hanano M,
    4. Tokui T,
    5. Komai T,
    6. Sugiyama Y
    (1993) Na+-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol 264:G36–G44.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleArticle

Transport of Temocaprilat into Rat Hepatocytes: Role of Organic Anion Transporting Polypeptide ,

Hitoshi Ishizuka, Kumiko Konno, Hideo Naganuma, Kenji Nishimura, Hirokazu Kouzuki, Hiroshi Suzuki, Bruno Stieger, Peter J. Meier and Yuichi Sugiyama
Journal of Pharmacology and Experimental Therapeutics October 1, 1998, 287 (1) 37-42;
Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement